Alphamab Oncology announces anti-HER2 biparatopic ADC JSKN003 obtained orphan drug designation from the U.S. FDA...

Zymeworks announces FDA clearance of investigational new drug application for ZW251, a novel glypican 3-targeted...

Chong Kun Dang’s ADC-based anticancer drug receives FDA approval for Phase 1/2 clinical trials

ESMO 2025, CStone Pharmaceuticals to disclose CS5001 ADC updated study design for the first time

JSKN003 received the U.S FDA approval to initiate a Phase 2 clinical study in the...

Owkin teams up with NeoGenomics and France Tissue Bank to build IHC-dedicated foundation model for...